· EPA3G a unique, patented emulsion of high purity EPA, in drinkable single sachet - containing daily dose of 3g
· Deal gives Noventure licensing rights in over 50 countries
· Agreement signed with global partner Azur Global Nutrition
Barcelona, Spain, February 17th, 2021 - Noventure announces today that it has signed an exclusivity agreement for the licensing of the innovative food supplement EPA3G, with global partner Azur – a division of Solutex (Madrid, Spain).
Within the marketplace, there is a huge offering in omega-3 supplements. There is much debate on the amount of omega-3 required to deliver meaningful health benefits and on what is a realistic dosage to suit everyday lifestyles. The current options of multiple servings, or those bulky, difficult-to-swallow capsules, are not ideal.
EPA3G successfully fills this market gap. With almost three grams of pure EPA (eicosapentaenoic acid) in one easy-to-take daily dose, EPA3G is a patented, state-of-the-art drinkable emulsion available in sachets, with excellent organoleptic properties (texture and smell) – these provide the highest EPA intake per dose.
Under the terms of the agreement, Noventure has the rights to license EPA3G to specialized companies. These must have marketing expertise and knowledge in the commercialization of high-end food supplements. The agreement covers over 50 countries on different continents, including all EU members and associated states, the UK, the Balkans, Russia, Ukraine, Eurasian countries, Mexico, Taiwan and several African states. The financial terms of the agreement have not been disclosed.
“Noventure’s mission is to shape innovative science assets and bring them to markets around the world. With this agreement, people will now have a differentiated, value-added omega-3 product, which is effective and easy to use,” said Luciano Conde, CEO of Noventure. “We are very pleased to work with Azur, together we will keep building strong partnerships based on a shared understanding of user’s needs and pursue market opportunities whilst growing together.”
“Globally, EPA is gaining importance and becoming a part of many consumer’s daily diet i . The key reasons for this market growth have been the increased prevalence of lifestyle diseases and people choosing preventive healthcare measures,” said Julio Boza, CEO of Azur. “Consumer desire for high effectiveness and bioavailability has also ensured manufacturers seek more highly concentrated forms to better provide efficacious doses of EPA. We are delighted to work with Noventure. We believe this technology will allow people to satisfy their omega-3 requirements in a convenient drinkable format. This is a great example of transforming bright science and technology into breakthrough, sustainable commercial solutions and is an example of how to work and grow together.”
The global EPA and DHA market is projected to grow at the CAGR of 8.26% during forecast period 2020 – 2025.
About Azur Global Nutrition/Solutex
Azur Global Nutrition develops and delivers unique, science-backed and data driven value-added products to the marketplace through extensive research and innovation specific to immune-nutrition. Azur offers ingredients, dietary supplements and medical food products derived from omega-3 ingredients and focused on balancing the lipid metabolism and homeostasis of the body for health and wellness.
Azur is a division of the Solutex Group, a biotechnology industry leader in the manufacture and commercialization of premium highly concentrated omega-3 fatty acids.
Noventure is a Spanish company based in Barcelona. It is specialized in licensing innovative substance-based medical devices and specialist food supplements. It markets approved medical devices under the CE Mark - ready for marketing in the EU and in territories around the world - and singular food supplements in the areas of gastroenterology, urogynecology, pediatrics and dermatology. Noventure’s innovative, substance‐based medical devices are patient-friendly effective solutions. The specialized food supplements come in distinctive galenic formulations, thereby increasing acceptability and adherence, and improving consumer experience.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.